Estatinas: ¿y si bajar el colesterol no reduce la mortalidad?
La Razon (ESP),
Sociedad Un metanálisis concluye que su empleo en personas sin otro tipo de marcador de riesgo cardiovascular que el LDL…
Jan 13 2023 This Week in Cardiology
Medscape,
Please note that the text below is not a full transcript and has not been copyedited.
Jan 6 2023 This Week in Cardiology
Medscape,
Please note that the text below is not a full transcript and has not been copyedited.
Zorgen over evolocumabstudie: ‘Doodsoorzaken verkeerd geregistreerd’
Medisch Contact ,
De cholesterolverlager evolocumab verhoogt mogelijk de kans op cardiovasculaire sterfte.
Recount of FOURIER data finds higher mortality with evolocumab; trialists push back
Pediatric News ,
Readjudication of mortality data from the FOURIER trial suggests a higher risk for cardiovascular death with evolocumab (Repatha…
Jan 6 2023 This Week in Cardiology
Medscape,
Please note that the text below is not a full transcript and has not been copyedited.
Recount of FOURIER Data Finds Higher Mortality With Evolocumab
Medscape,
Readjudication of mortality data from the FOURIER trial suggests a higher risk for cardiovascular death with evolocumab (Repatha…
Reanalysis of key trial flags fresh safety concerns for Amgen’s Repatha
PharmaLive,
Published: Jan 04, 2023 By Tristan Manalac BioSpace A reanalysis of data from the FOURIER trial found a higher risk of…
Reanalysis of Key Trial Flags Fresh Safety Concerns for Amgen’s Repatha (Upda...
Biospace,
Courtesy of Amgen A reanalysis of data from the FOURIER trial found a higher risk of cardiovascular death associated with Amgen’s…
Experts Issue Caution for Evolocumab Following New Review of FOURIER Data
AJMC,
A strong warning has been issued for evolocumab by researchers from Spain and Canada on use of the proprotein convertase…
Amgen's Repatha under fire over cardiovascular outcomes data in key trial
Seeking Alpha,
Amgen's PCSK9 inhibitor for lowering cholesterol, Repatha (evolocumab), may lead to cardiac harm, according to a reassessment…